P019 Cutaneous amyloidoma: a rare variant of primary cutaneous marginal zone lymphoproliferative disorder

Sarah Fleming,Shane Brennan,Kevin Molloy

DOI: https://doi.org/10.1093/bjd/ljae090.046

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract A 71-year-old male patient presented to the dermatology department with a nontender erythematous nodule on the left arm. Incisional biopsy illustrated a dermal-based perivascular plasma-cell infiltrate with kappa-light chain restriction. There was also marked deposition of dermal amorphous eosinophilic material, with similar amorphous material deposition within vessel walls. Apple green birefringence under polarized light with Congo red staining was observed. Review at the UK National Amyloidosis Centre concluded that this was consistent with cutaneous amyloid-L (AL) amyloidosis. A bone marrow trephine and PET-CT ruled out systemic involvement. The patient was listed for surgical resection and monitored clinically by the dermatology and haematology teams. Amyloidosis represents a spectrum of disease including systemic and localized cutaneous subtypes. There is much discussion regarding the nosology of AL amyloidosis; however, there is consensus among clinicians, who consider cutaneous amyloidoma to be a rare variant (< 1%) of primary cutaneous marginal zone lymphoproliferative disorder. Cutaneous amyloidoma presents as small waxy nodules and/or plaques usually located on the extremities, and is histologically characterized by prominent amyloid deposition and few perivascular plasma cells. Surgical excision is the treatment of choice. AL amyloidosis presents in an older population and has a more indolent clinical course compared with the systemic subtype, leading to the proposal that cutaneous amyloidosis (AL type) may represent a precursor to the systemic process. Although progression to high-grade lymphoma or systemic amyloidosis is rare, it is recommended that patients undergo staging of the disease, eradication of the cutaneous disease and close clinical follow-up. Classification of cutaneous AL amyloidosis is hindered by its rarity; however, the authors hope that this case will add to the growing literature available on the condition.

dermatology